Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

Mapping Intimacies ◽

10.1158/1538-7445.sabcs16-p6-11-03 ◽

2017 ◽

Author(s):

IA Mayer ◽

CL Arteaga ◽

R Nanda ◽

KD Miller ◽

K Jhaveri ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label Study ◽

Download Full-text

Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

10.1158/1538-7445.sabcs19-gs1-03 ◽

2020 ◽

Author(s):

Ian E Krop ◽

Cristina Saura ◽

Toshinari Yamashita ◽

Yeon Hee Park ◽

Sung-Bae Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label Study ◽

Label Study ◽

Previously Treated

Download Full-text

P3-16-18: Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-p3-16-18 ◽

2011 ◽

Author(s):

JA O'Shaughnessy ◽

CRC Osborne ◽

MA Steinberg ◽

FA Holmes ◽

HS Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label Study ◽

Label Study ◽

Previously Treated

Download Full-text

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps1102 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS1102-TPS1102 ◽

Author(s):

Jose Baselga ◽

Kenji Tamura ◽

Toshinari Yamashita ◽

Shanu Modi ◽

Eriko Tokunaga ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label Study ◽

Label Study ◽

Previously Treated

Download Full-text

S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-s5-7 ◽

2011 ◽

Author(s):

M Martin ◽

J Bonneterre ◽

CE Geyer ◽

Y Ito ◽

J Ro ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

Open Label Study ◽

Download Full-text

Abstract OT1-1-17: LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib*

10.1158/0008-5472.sabcs12-ot1-1-17 ◽

2012 ◽

Author(s):

T Hickish ◽

A Mehta ◽

M Jain ◽

C-S Huang ◽

N Kovalenko ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

Open Label Study ◽

Download Full-text

Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients

Annals of Oncology ◽

10.1093/annonc/mdw365.59 ◽

2016 ◽

Vol 27 ◽

pp. vi87

Author(s):

H. McArthur ◽

D. Page ◽

T. Proverbs-Singh ◽

S. Solomon ◽

C. Hudis ◽

...

Keyword(s):

Breast Cancer ◽

Gene Therapy ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Open Label Study ◽

Label Study ◽

Download Full-text

1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy

European Journal of Cancer ◽

10.1016/s0959-8049(16)30839-5 ◽

2015 ◽

Vol 51 ◽

pp. S295-S296

Author(s):

A. Wong ◽

L.Z. Wang ◽

F.C. Wong ◽

S. Ow ◽

K. Nesaretnam ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Predictive Marker ◽

Open Label Study ◽

Label Study ◽

Post Menopausal

Download Full-text

Abstract OT2-6-09: 4EVER - A phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)

10.1158/0008-5472.sabcs13-ot2-6-09 ◽

2013 ◽

Author(s):

H Tesch ◽

PA Fasching ◽

P Hadji ◽

DI Lueftner ◽

W Janni ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Open Label Study ◽

Label Study ◽

Estrogen Receptor Positive

Download Full-text

Abstract OT2-01-18: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole

10.1158/1538-7445.sabcs16-ot2-01-18 ◽

2017 ◽

Author(s):

PA Fasching ◽

T Decker ◽

T Fehm ◽

W Janni ◽

S Kuemmel ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Open Label Study ◽

Label Study ◽

Estrogen Receptor Positive

Download Full-text

Abstract OT3-1-08: The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

10.1158/0008-5472.sabcs13-ot3-1-08 ◽

2013 ◽

Author(s):

IH Park ◽

KS Lee ◽

S-A Im ◽

KH Jung ◽

KH Park ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label Study ◽

Label Study ◽

Previously Treated

Download Full-text